Dadx2 & Hubby & Med Oncologist. Current @csoncol fellow. Interested in Time Tox, Pt Prefs, Value in Cancer Care. Views=own.
Kingston, Ontario, Canada
Joined January 2018
- Tweets343
- Following832
- Followers302
- Likes1.8K
Sam Stevens retweeted
New paper published in @ecancer on travel burden for patients with colorectal cancer in Kashmir, India. ecancer.org/en/journal/artic…
The first author of this paper is Dr. Saquib Banday who was paired with @oncology_bg for 2022 @myESMO virtual mentorship program.
Sam Stevens retweeted
Cancer care and movement: a new economic analysis of the landmark CHALLENGE clinical trial shows that a supervised exercise program after adjuvant chemotherapy not only improves colon cancer patient survival, it also reduces costs to our health system. Adopting exercise as a standard anti-cancer treatment would mean fewer cancer recurrences and improved survival for patients, and lower treatment costs for our health system. Read more in the Toronto Star.
tinyurl.com/pas9fvtr
#CommonSenseOncology #CancerCare
ALT Exercise as anti-cancer treatment. A person running in an urban landscape.
Sam Stevens retweeted
Let us please ban at #ASCO18:
* “Trend towards statistical significance”
* Subgroup overinterpretation
* Forest plot mangling
The old saying: if you torture the data long enough, it will confess.
Great to talk to Josh from @HemOncToday about this work!
❓Is #TimeToxicity too negative?
Patients, caregivers and oncologists say “toxicity” could communicate judgement on #cancer care choices.
📹 Time commitment, time impact or time trade-off may be more “approachable.” @SamuelXStevens @csoncol @queensu
🔗 bit.ly/40mtzR4
Sam Stevens retweeted
❓Is #TimeToxicity too negative?
Patients, caregivers and oncologists say “toxicity” could communicate judgement on #cancer care choices.
📹 Time commitment, time impact or time trade-off may be more “approachable.” @SamuelXStevens @csoncol @queensu
🔗 bit.ly/40mtzR4
Sam Stevens retweeted
We invite those from the Pacific and beyond to join us for the inaugural webinar of the Common Sense Oncology Pacific Hub!
Join us on Thursday, February 26 at 5 pm AWDT / 7 pm AEDT / 9 pm NZT to discuss the challenges and opportunities in oncology in the Pacific and how CSO can better serve the needs of the region.
Register on Zoom: tinyurl.com/us5vbct9
#CommonSenseOncology #CancerCare
ALT Common Sense Oncology Pacific Hub. Inaugural Webinar: Thursday, February 26, 2026, at 5 pm AWDT / 7 pm AEDT / 9 pm NZT. Featured speakers: Dr. Deme Karikios, Nepean Hospital; Dr. Samuel Stevens, Common Sense Oncology; Prof. Christopher Jackson, Mercy Hospital. Learn about the challenges and opportunities in oncology in the Pacific and discuss how CSO can better serve the needs of your region.
⁉️ Just out JCO OP: Stakeholder Perspectives on “Time Toxicity”
🕰️ “Time toxicity” has gained traction in oncology, highlighting the hidden burden of patients’ time. But does this language reflect stakeholder experiences of time spent on treatment?
Read: ascopubs.org/doi/10.1200/OP-…
Sam Stevens retweeted
We are proud to release our @OncologyBGLab’s 2025 Annual Report. You can read about all exciting things we did in 2025, and what we have in plans for 2026. oncologybg.com/wp-content/up…
Sam Stevens retweeted
The NHMRC yesterday announced final allocations for the year. The 2025 success rate for Ideas grants was 10%, Investigator grants 13%, and Clinical Trials 9%.
Australia's total spend on healthcare and technology innovation in medicine and biotech from the Medical Research Endowment Account and Medical Research Future Fund this year will equate to the cost of 0.004 submarines.
We're spending more on a single submarine than we'll spend on medical research in 30 years.
Medical research matters. A clever country invests in the things that matter.
Sam Stevens retweeted
Finally, good to see some positive development from this FDA. Requiring RCT with survival endpoint for CAR-T regular approval is a very positive step.
Also, it continues to baffle me how papers coming out of FDA, NCI, etc can be behind a paywall. Why aren’t all these papers open access?
jamanetwork.com/journals/jam…
‘Shared Decision Making is about what makes sense for THIS patient; it is a method of care; it is NOT an extra thing to do. We need to create the conditions for care to occur in our health systems.’ Fantastic insights by Prof Victor Montori at @LHSCCanada
Sam Stevens retweeted
The rise of subcutaneous immunotherapy isn’t just about convenience, it’s about patents, pricing strategies, and delayed biosimilars.
Can healthcare systems afford years of high prices when IV biosimilars could generate huge savings?
Brilliant and provocative viewpoint. @Timothee_MD @DoniaMarco
#CancerCare #HealthEconomics #ImmunoOncology thelancet.com/journals/lanon…
Sam Stevens retweeted
New open access paper from @OncologyBGLab !
In this new paper led by my colleague @RamilaShilpakar and my trainee @brianshkabarii , we find that some cancer drugs’ prices in Nepal can vary by up to almost 1000% based on which hospital you go to or which brand you choose! Many drug’s are unavailable and when available, they are unaffordable. The ground reality of #globaloncology ! ascopubs.org/doi/10.1200/GO-…
Sam Stevens retweeted
My first paper as a single author is out in the European Journal of Cancer!
"Identifying informative censoring from censoring patterns across successive follow-ups."
Before a longer post on The Oncology Shot, here is a tweetorial.
1/7
Sam Stevens retweeted
Wow! Not one, 2 @JCO_ASCO articles in less than 2 months "defending" adjuvant CDK4/6 inhibitors in patients with early breast cancer!
Parlty in response of our works @vkprasadlab
Stakes are high, up to 40% of patients with newly diagnosed breast cancer could be eligible.
👉For an alternative perspective on the data, see The Oncology Shot !
(+ more on that topic soon, stay tuned)
